MEN1 and multiple endocrine neoplasia type 1: It would be interesting to periodically evaluate levels of serum miRNAs in MEN1 mutation carriers who have not yet developed any signs or symptoms of MEN1 syndrome and are not undergoing any medical treatment, to monitor how c-miRNA levels can vary with the progression of the disease and whether they could be early indicators of tumor occurrence.